A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Cinolazepam
Dexamethasone isonicotinate
The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Hydrocortisone butyrate.
Cinolazepam
Meprednisone
The risk or severity of adverse effects can be increased when Meprednisone is combined with Hydrocortisone butyrate.
Cinolazepam
Fluprednisolone
The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Hydrocortisone butyrate.
Cinolazepam
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Hydrocortisone butyrate.
Cinolazepam
Peginterferon beta-1a
The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Hydrocortisone butyrate.
Cinolazepam
Tixocortol
The risk or severity of adverse effects can be increased when Tixocortol is combined with Hydrocortisone butyrate.
Cinolazepam
Vilanterol
The risk or severity of adverse effects can be increased when Vilanterol is combined with Hydrocortisone butyrate.
Cinolazepam
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Hydrocortisone butyrate.
Cinolazepam
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Hydrocortisone butyrate.
Cinolazepam
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Hydrocortisone butyrate.
Cinolazepam
Fluprednidene
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Hydrocortisone butyrate.
Cinolazepam
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Hydrocortisone butyrate.
Cinolazepam
Dimethyl fumarate
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Hydrocortisone butyrate.
Cinolazepam
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Hydrocortisone butyrate.
Cinolazepam
Eribulin
The risk or severity of adverse effects can be increased when Eribulin is combined with Hydrocortisone butyrate.
Cinolazepam
Wortmannin
The risk or severity of adverse effects can be increased when Wortmannin is combined with Hydrocortisone butyrate.
Cinolazepam
Bendamustine
The risk or severity of adverse effects can be increased when Bendamustine is combined with Hydrocortisone butyrate.
Cinolazepam
Belatacept
The risk or severity of adverse effects can be increased when Belatacept is combined with Hydrocortisone butyrate.
Cinolazepam
Abetimus
The risk or severity of adverse effects can be increased when Abetimus is combined with Hydrocortisone butyrate.
Cinolazepam
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Hydrocortisone butyrate.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3